GSK: positive results for depemokimab in severe asthma
The company reports that the trials met the 52-week target for reducing asthma exacerbations, and showed similar rates of adverse events between depemokimab and placebo.
Depemokimab, administered twice a year, targets interleukin-5 (IL-5) to reduce inflammation.
Full results will be presented at a scientific congress and used for regulatory submissions. Depemokimab is not yet approved, GSK adds.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction